Pages that link to "Q24605691"

The following pages link to CYP51 structures and structure-based development of novel, pathogen-specific inhibitory scaffolds (Q24605691):

Displaying 24 items.

• Organocatalytic, enantioselective synthesis of VNI: a robust therapeutic development platform for Chagas, a neglected tropical disease (Q24597322) (← links)
• VNI cures acute and chronic experimental Chagas disease (Q24604994) (← links)
• Complexes of Trypanosoma cruzi Sterol 14 -Demethylase (CYP51) with Two Pyridine-based Drug Candidates for Chagas Disease: STRUCTURAL BASIS FOR PATHOGEN SELECTIVITY (Q27679983) (← links)
• Architecture of a single membrane spanning cytochrome P450 suggests constraints that orient the catalytic domain relative to a bilayer (Q27682064) (← links)
• Structural Basis for Rational Design of Inhibitors Targeting Trypanosoma cruzi Sterol 14α-Demethylase: Two Regions of the Enzyme Molecule Potentiate Its Inhibition (Q27684715) (← links)
• Sequence variation in CYP51A from the Y strain of Trypanosoma cruzi alters its sensitivity to inhibition (Q34614864) (← links)
• Drug strategies targeting CYP51 in neglected tropical diseases (Q34622554) (← links)
• Binding mode and potency of N-indolyloxopyridinyl-4-aminopropanyl-based inhibitors targeting Trypanosoma cruzi CYP51. (Q34701325) (← links)
• Dynamics of CYP51: implications for function and inhibitor design (Q35110082) (← links)
• Structure-Functional Characterization of Cytochrome P450 Sterol 14α-Demethylase (CYP51B) from Aspergillus fumigatus and Molecular Basis for the Development of Antifungal Drugs (Q36093075) (← links)
• VFV as a New Effective CYP51 Structure-Derived Drug Candidate for Chagas Disease and Visceral Leishmaniasis (Q36148993) (← links)
• Different Therapeutic Outcomes of Benznidazole and VNI Treatments in Different Genders in Mouse Experimental Models of Trypanosoma cruzi Infection (Q36290550) (← links)
• In vitro and in vivo studies of the antiparasitic activity of sterol 14α-demethylase (CYP51) inhibitor VNI against drug-resistant strains of Trypanosoma cruzi. (Q37124209) (← links)
• Design or screening of drugs for the treatment of Chagas disease: what shows the most promise? (Q37401820) (← links)
• Two analogues of fenarimol show curative activity in an experimental model of Chagas disease. (Q37449720) (← links)
• Targeting CYP51 for drug design by the contributions of molecular modeling. (Q38917135) (← links)
• Novel 3-nitrotriazole-based amides and carbinols as bifunctional antichagasic agents (Q38920814) (← links)
• Antitrypanosomal Activity of Sterol 14α-Demethylase (CYP51) Inhibitors VNI and VFV in the Swiss Mouse Models of Chagas Disease Induced by the Trypanosoma cruzi Y Strain (Q40342687) (← links)
• Human sterol 14α-demethylase as a target for anticancer chemotherapy: towards structure-aided drug design (Q42266154) (← links)
• A convergent, scalable and stereoselective synthesis of azole CYP51 inhibitors (Q49679428) (← links)
• CYP51 as drug targets for fungi and protozoan parasites: past, present and future. (Q52593361) (← links)
• Synthesis and Biological Activity of Sterol 14α-Demethylase and Sterol C24-Methyltransferase Inhibitors (Q58842234) (← links)
• Advances in preclinical approaches to Chagas disease drug discovery (Q92610556) (← links)
• Sterol 14α-Demethylase Structure-Based Optimization of Drug Candidates for Human Infections with the Protozoan Trypanosomatidae (Q93207221) (← links)